Claire Mazumdar Sells 3,817 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $18.75, for a total transaction of $71,568.75. Following the completion of the transaction, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at $6,363,600. This trade represents a 1.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.73, for a total transaction of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.74, for a total transaction of $33,469.64.

Bicara Therapeutics Stock Down 0.2%

Shares of BCAX opened at $18.47 on Friday. Bicara Therapeutics Inc. has a twelve month low of $7.80 and a twelve month high of $19.71. The company has a market capitalization of $1.01 billion, a P/E ratio of -8.25 and a beta of -0.78. The firm has a 50 day moving average of $16.47 and a 200 day moving average of $15.78.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds have recently added to or reduced their stakes in BCAX. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Bicara Therapeutics during the 4th quarter valued at $45,000. Legal & General Group Plc grew its holdings in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the period. Ameritas Investment Partners Inc. increased its position in Bicara Therapeutics by 73.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after acquiring an additional 1,474 shares during the last quarter. Larson Financial Group LLC increased its position in Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after acquiring an additional 3,595 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after acquiring an additional 3,866 shares during the period.

Bicara Therapeutics News Summary

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Several institutional investors increased or initiated positions in BCAX recently (e.g., Woodline, Geode, Nan Fung, AQR), which supports demand from professional managers and can offset selling pressure. Read More.
• Positive Sentiment: Analyst coverage remains largely favorable — multiple firms maintain Buy/Outperform ratings and the consensus price target sits well above the current price, providing a bullish backdrop for longer‑term holders. Read More.
• Neutral Sentiment: The company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) for a new hire — routine for growth‑stage biotech but can add modest dilution expectations. Read More.
• Neutral Sentiment: Published short‑interest entries for early March report “large increases” but show 0 shares/NaN changes — the data appears erroneous and does not provide reliable evidence of increased shorting. (No actionable short‑sale signal.)
• Negative Sentiment: CFO Ivan Hyep sold stock across March 3–4 (totaling 16,518 shares across recent sales), reducing his stake; sizable CFO sales can sap near‑term sentiment. Read More.
• Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 (~7.8% reduction in his holding). Executive selling at this scale may be viewed as liquidity‑taking and can pressure the share price. Read More.
• Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (including a 16,300‑share sale), representing a large reduction in one filing; founder/executive selling is commonly interpreted negatively by the market. Read More.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Citizens Jmp started coverage on Bicara Therapeutics in a report on Thursday, January 29th. They issued a “market perform” rating and a $31.00 target price for the company. BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Wells Fargo & Company boosted their target price on Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Finally, UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Seven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.33.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.